Table 1.
Analysis of drug combination effects
| Citarinostat (µm) | Momelotinib (µM) | CI (CI 95%) |
|---|---|---|
| WSU-NHL | ||
| 2 | 0.5 | 0.30 (0.06–1.39) |
| 4 | 1 | 0.45 (0.06–2.77) |
| RL | ||
| 2 | 0.5 | 0.14 (0.03–0.28) |
| 4 | 1 | 0.13 (0.02–0.91) |
| KARPAS422 | ||
| 2 | 0.5 | 0.34 (0.23–0.49) |
| 4 | 1 | 0.13 (0.17–0.42) |
| MEC1 | ||
| 2 | 0.5 | 0.35 (0.28–0.43) |
| 4 | 1 | 0.16 (0.12–0.22) |
| GRANTA519 | ||
| 2 | 0.5 | 1.21 (0.15–1.66) |
| 4 | 1 | 1.76 (0.35–3.93) |
| JEKO1 | ||
| 2 | 0.5 | 0.09 (0.02–0.36) |
| 4 | 1 | 0.09 (0.02–0.55) |
| HUT78 | ||
| 2 | 0.5 | 0.19 (0.04–0.89) |
| 4 | 1 | 0.16 (0.02–1.68) |
| KARPAS299 | ||
| 2 | 0.5 | 0.98 (0.16–1.71) |
| 4 | 1 | 0.52 (0.14–2.52) |
| L1236 | ||
| 2 | 0.5 | 1.21 (0.36–4.04) |
| 4 | 1 | 1.17 (0.37–3.73) |
| L540 | ||
| 2 | 0.5 | 0.57 (0.27–1.22) |
| 4 | 1 | 0.05 ( 0 − 0.74) |
| RPMI8226 | ||
| 2 | 0.5 | 0.16 (0.04–0.63) |
| 4 | 1 | 0.02 (0.01–0.34) |
| U266 | ||
| 2 | 0.5 | 0.18 (0.08–0.40) |
| 4 | 1 | 0.17 (0.04–0.80) |
Combination Index (CI) of citarinostat (2, 4 µM) in combination with momelotinib (0.5, 1 µM) after 24 h of treatment. Synergism, additivity, or antagonism were quantified by determining the CI calculated by the Chou–Talalay equation. Combination index (CI) CI < 1, synergism; CI = 1, additive effect; CI > 1, antagonism